Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Ralph DeFronzo, MD
Credit: UT Health San Antonio

 was nearly twice as common in individuals with resistant hypertension and an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m² as in those with preserved kidney function, according to a kidney-stratified analysis of the MOMENTUM study presented at the 

The data come less than a week after Corcept Therapeutics announced the resubmission of its New Drug Application for relacorilant as a treatment for patients with hypercortisolism to the US Food and Drug Administration on June 17, 2026. This resubmission is based on the GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, relacorilant’s long-term extension study, and earlier-stage development data.

“MOMENTUM showed that individuals with rHTN and reduced kidney function have an elevated risk of HC, supporting the need for targeted screening in this high-risk population,” wrote investigators, who were led by Ralph DeFronzo, MD, of UT Health San Antonio. 

MOMENTUM (NCT06829537) is the first US-based trial to assess endogenous hypercortisolism in resistant hypertension, where the relationship between reduced kidney function and hypercortisolism has been poorly characterized. Funded by Corcept Therapeutics, the US, multicenter, prospective, observational study screened adults aged 18 years or older with resistant hypertension per American Heart Association criteria. 

The original study was presented by Deepak Bhatt, MD, MPH, MBA, of Mount Sinai, as a late-breaker at the American College of Cardiology 2026 (ACC.26) Scientific Sessions. Results presented at ACC.26 indicated 297 of the 1086 patients screened, or 27.3%, met the study definition for hypercortisolism. Among the subset of participants with hemoglobin A1c of 7.5% or higher who were taking 3 or more antihypertensive medications, the prevalence rose to 32.6%.

Investigators used the 1-mg overnight dexamethasone suppression test (DST), defining hypercortisolism as a post-DST cortisol greater than 1.8 μg/dL. Individuals with conditions confounding DST interpretation were excluded, and a historical eGFR below 30 mL/min/1.73 m² was exclusionary, though baseline eGFR was used for this analysis.

Among 1086 participants, 140 (12.9%) had an eGFR below 45 mL/min/1.73 m², 203 (18.7%) had an eGFR of 45 to 59 mL/min/1.73 m², and 743 (68.4%) had an eGFR of 60 mL/min/1.73 m² or higher. Hypercortisolism prevalence rose as kidney function declined, reaching 43.6% in the lowest eGFR subgroup, 30.0% in the middle subgroup, and 23.6% in the highest subgroup. The difference across groups was significant (

Kidney Function Markers and CKD Progression Risk by Hypercortisolism Status

Participants with hypercortisolism had a lower mean eGFR than those without hypercortisolism (63.8 vs 71.9 mL/min/1.73 m²; 

 < .0001). Mean urine albumin-to-creatinine ratio (UACR) trended higher in the hypercortisolism group (234.7 vs 139.9 mg/g; 

Hypercortisolism frequency also climbed across worsening chronic kidney disease (CKD) progression risk categories, with the highest prevalence in the very-high-risk group (

 < .0001 for any difference across groups). When further stratified, the proportion of participants with a post-DST cortisol above 1.8 μg/dL reached 49% at an eGFR below 30 mL/min/1.73 m² and 42% at 30 to 44 mL/min/1.73 m², compared with 22% at an eGFR of 90 mL/min/1.73 m² or higher.

Morning adrenocorticotropic hormone and post-DST cortisol values were broadly comparable across eGFR subgroups, though mean post-DST cortisol was modestly higher in participants with reduced renal function. The investigators noted the analysis could not determine whether the association reflects a true disruption of the hypothalamic-pituitary-adrenal axis or methodologic effects of the uremic state on cortisol measurement.

DeFronzo RA, Aroda VR, Basile JN, et al. Prevalence of endogenous hypercortisolism in individuals with resistant hypertension stratified by kidney function: results from the MOMENTUM study. Presented at: 10th Annual Heart in Diabetes Meeting; June 19-21, 2026. Abstract 0055.

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome. Corcept Therapeutics, Incorporated. Published June 17, 2026. Accessed June 21, 2026. 

https://ir.corcept.com/news-releases/news-release-details/corcept-resubmits-new-drug-application-relacorilant-treatment/

Campbell P. MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. Hcplive.com. Published March 29, 2026. Accessed June 21, 2026. 

https://www.hcplive.com/view/momentum-hypercortisolism-present-in-1-in-4-with-resistant-hypertension

Articles

Endogenous hypercortisolism prevalence increased stepwise with declining renal function among adults with resistant hypertension in the US multicenter, prospective MOMENTUM study. Using a 1-mg overnight dexamethasone suppression test threshold of post-DST cortisol >1.8 μg/dL, hypercortisolism reached 43.6% at eGFR <45 versus 23.6% at eGFR ≥60 mL/min/1.73 m² (P<.0001). Hypercortisolism was associated with lower mean eGFR and numerically higher UACR, supporting targeted screening in higher CKD-risk strata.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

MOMENTUM: Lower Kidney Function Could Signal Hypercortisolism in Resistant Hypertension

A trio of analyses from LIBERTY AD PEDS, LIBERTY AD PRESCHOOL, and the long-term PED-OLE extension study show dupilumab (Dupixent) improves growth attainment in school-age children, provides rapid caregiver-reported symptom relief in infants and toddlers, and sustains regional skin improvements across body regions for up to 3 years in children with 

Revolutionizing Atopic Dermatitis (RAD) 2026 Conference

, the analyses span the youngest patients in dupilumab's development program, from infants as young as 6 months through children aged 11 years, and document benefits ranging from improved height percentile gain to reduced caregiver burden during the first 2 weeks of treatment.

"Dupilumab treatment for up to 3 years demonstrated sustained efficacy across all anatomic regions in children aged 6 months to 11 years with moderate-to-severe AD, with safety consistent with the known safety profile of dupilumab," the PED-OLE investigators concluded.

Growth Improvement in Children 6-11 Years and Caregiver Impressions in Under-5s

In the LIBERTY AD PEDS growth analysis, children aged 6 to 11 years with severe AD who were below the 30th height percentile at baseline showed significantly greater height gain with dupilumab than placebo over 16 weeks. The proportion achieving at least a 5-percentile improvement in height-for-age was 31.9% with dupilumab versus 11.1% with placebo (

Logistic regression models confirmed the growth benefit remained significant after adjustment for cumulative topical corticosteroid (TCS) dose (Odds Ratio, 4.21; 95% CI, 1.40-12.63; 

= .010), indicating dupilumab's effect appears independent of reduced TCS use.

In LIBERTY AD PRESCHOOL, caregivers of infants and children aged 6 months to 5 years reported significantly better Caregiver Global Impression of Disease  scores, indicating no or mild symptoms, with dupilumab versus placebo from week 2, the earliest timepoint measured. By week 16, 51.8% of caregivers in the dupilumab group reported no or mild symptoms versus 5.5% with placebo.

On the Caregiver Global Impression of Change, 67.1% of caregivers in the dupilumab group rated symptoms as much better or moderately better at week 16 versus 11.2% with placebo (

<.0001), a difference of 55.9 percentage points.

The PED-OLE open-label extension (NCT02612454) enrolled children from both LIBERTY AD PRESCHOOL (ages 6 months to 5 years; N=180) and LIBERTY AD PEDS (ages 6-11 years; N=383), providing up to 152 weeks of continuous dupilumab data. The analysis examined EASI-75 and EASI-90 by anatomic region: head, trunk, upper extremities, and lower extremities.

In children aged 6 months to 5 years at week 52, EASI-90 response rates were 91.9% for head/neck, 81.8% for trunk, 85.4% for upper extremities, and 77.7% for lower extremities. In the 6-11 year age group at week 152, EASI-90 rates were 80.9% for head, 77.7% for trunk, 86.4% for upper extremities, and 75.3% for lower extremities.

Treatment-emergent adverse events led to permanent discontinuation in 1.1% of the younger cohort and 0.8% of the older cohort. Drug-related serious treatment-emergent adverse events were infrequent (0.6% and 0.3%).

Irvine AD, Paller AS, Siegfried EC, et al. Growth improvement in children 6 to 11 years with severe atopic dermatitis treated with dupilumab irrespective of TCS use. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Weibel L, Prajapati VH, Vainder E, et al. Caregiver impressions of disease and change in infants and children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Paller AS, Siegfried EC, Pinter A, et al. Long-term dupilumab treatment resulted in consistent improvements across anatomic regions in pediatric patients with moderate-to-severe atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Dupilumab Improves Growth, Skin, & Caregiver Burden Across Pediatric AD Spectrum

 testing prevalence was just 1.1% among US adults, while a companion at-home screening program identified elevated LDL-C and/or lipoprotein(a) levels in nearly two-thirds of results returned.

Current dyslipidemia guidelines recommend lipoprotein(a) measurement at least once during adulthood, yet adoption of universal testing has lagged. In data presented at the 

, the Family Heart Foundation examined both sides of this gap: how often lipoprotein(a) is ordered in routine claims data, and what happens when free at-home testing removes the access barrier.

Lp(a) testing prevalence and racial disparities

Investigators analyzed the Family Heart Database, a claims and laboratory repository spanning 350 million US individuals from 2012 to 2024, to assess Lp(a) testing prevalence in adults tested during 2023 to 2024. Among all adults in the cohort (2,063,830 of 187,594,288), Lp(a) testing prevalence was 1.1%.

Prevalence rose to 2.6% among adults with a standard lipid profile, 2.8% among those with established 

 (ASCVD), and 5.7% among adults with both ASCVD and a lipid profile on record.

Diabetes (adjusted odds ratio [aOR], 0.78; 95% CI, 0.78 to 0.79; 

 < .0001) and stage III to V chronic kidney disease (aOR, 0.88; 95% CI, 0.87 to 0.89; 

 < .0001) were both associated with lower odds of Lp(a) testing relative to adults without those conditions. Greater Charlson Comorbidity Index scores followed a similar inverse pattern, with adults carrying a comorbidity index of 8 or more 26% less likely to be tested than those with no comorbidities (aOR, 0.74; 95% CI, 0.72 to 0.75; 

Repeat testing occurred in 25.1% (517,125 of 2,063,830) of adults with an initial Lp(a) result. In multivariable regression, familial hypercholesterolemia carried the strongest independent association with testing (aOR, 2.44; 95% CI, 2.38 to 2.49; 

 < .0001), followed by high LDL-C, non-statin lipid-lowering therapy, established coronary artery disease, and age over 40 years. White adults were 87% more likely to undergo Lp(a) testing than Black adults (aOR, 1.87; 95% CI, 1.85 to 1.88; 

 < .0001), a disparity investigators flagged as a target for intervention.

The Family Heart Foundation launched Cholesterol Connect in September 2024 to provide free at-home LDL-C and Lp(a) screening paired with Care Navigator support. According to the study, kit orders reached 30,950 through March 2026, outpacing the program's original projections. Among the first 8675 kits with results, 41% (3556) showed elevated LDL-C alone, 13% (1096) showed elevated LDL-C and Lp(a), and 11% (977) showed elevated Lp(a) alone.

User satisfaction, measured among 5,300 individuals who returned kits between March 2025 and March 2026, produced a Net Promoter Score of 73.8 against an industry benchmark range of -10 to 19. Respondents cited the program's free cost, simple process, and access to actionable health information as key drivers of satisfaction. 

Among adults who received an email invitation for 1-on-1 support after a high result, 15% engaged with a Care Navigator between November 2025 and March 2026.

Investigators on both posters called for strategies to close persistent testing gaps, including efforts to improve screening kit return rates and expand engagement with Family Heart Care Navigation.

Bardach SH, Brugger C, Hawke A, Wilemon K, MacDougall D, Paige H. Reducing gaps in cardiovascular risk factor awareness through free at-home LDL-C and lipoprotein(a) screening and support: insights from the first 30,950 tests ordered through the Family Heart Foundation Cholesterol Connect program. Presented at: 10th Annual Heart in Diabetes; June 19-21, 2026; Philadelphia, PA.

MacDougall DE, Baum S, Sperling L, Hartsuff B, Paige H, Wilemon KA. Prevalence and associated determinants of lipoprotein(a) testing in a contemporary cohort of US adults from the Family Heart Database. Presented at: 10th Annual Heart in Diabetes; June 19-21, 2026; Philadelphia, PA.

HCPLive. Updated ACC/AHA dyslipidemia guidelines incorporate LDL-C goals, Lp(a) focus, with Deepak Bhatt, MD, MPH. 

https://www.hcplive.com/view/updated-acc-aha-dyslipidemia-guidelines-incorporate-ldl-c-goals-lp-a-focus-with-deepak-bhatt-md-mph

. Published March 25, 2026. Accessed June 20, 2026.

Routine lipoprotein(a) [Lp(a)] testing remains rare in US adults despite guideline support for at-least-once lifetime measurement. Claims and laboratory data from 2012–2024 showed only 1.1% testing prevalence in 2023–2024, with modest enrichment in ASCVD and lipid-profile subgroups and lower testing odds in diabetes and advanced CKD. Marked racial disparities favored White adults. A free at-home LDL-C/Lp(a) program rapidly scaled, with nearly two-thirds of returned kits revealing elevated LDL-C and/or Lp(a), high user satisfaction, and limited uptake of navigator support.

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Lipoprotein(a) Testing Prevalence Remains Just 1.1% in US Adults

Revolutionizing Atopic Dermatitis (RAD) Conference

 spoke in an interview with Mona Shahriari, MD, associate clinical professor of dermatology at Yale School of Medicine and associate director of clinical trials at Central Connecticut Dermatology Research, who discussed several emerging themes shaping the future of atopic dermatitis management.

Shahriari, also known for her role as host of 

, touched on the therapeutic landscape’s expansion, highlighting a variety of developments that may further transform treatment strategies. She further emphasized the importance of helping patients navigate an increasingly complex array of options. Outside of novel therapies, Shahriari also noted the practical realities of managing chronic inflammatory disease in everyday practice.

 followed her RAD presentation, which she also highlighted during the interview.

 The following transcription covers Shahriari’s responses to inquiries about these topics:

There is so much going on today in the atopic dermatitis treatment landscape. What recent developments are most exciting to you?

I think one of the biggest revelations in the treatment landscape is the [news about] OX40-targeting drugs. Up until now, a lot of our drugs had been suppressing inflammation, but the OX40 pathway gives us the potential for a drug that can maybe retrain and even rebalance your immune system and give you the potential for disease modification. They are not by far the fastest drugs in the world, but for them it's more of a marathon and not a sprint.

Obviously, we're going to be watching their safety closely because of some of the signals that we've seen in phase three trials thus far, but I think just targeting the pathway a little bit differently, above the level of the cytokines, above the level of the T-cells that make those cytokines, and really going into that inflammatory prequel really has the potential to give us a different level of skin clearance.

Counseling patients with atopic dermatitis is necessary in dermatology. What are some key ways for clinicians to counsel patients with the inflammatory skin disease?

 I feel like prevention is the best thing to do. I counsel them from day one, so that we can avoid the impatience coming down the road. I kind of feel for my AD patients. People think these patients will put up with a lot because they've had their disease for so long. I actually think the contrary; we promised them the world as a specialty and we failed miserably. So, when a treatment is not working, they're very quick to think, ‘This is just like all the other treatments that I've gotten. Why should I stick with it?’

At the get-go, I tell them, ‘All right, this is the realistic expectation of what you can expect in four weeks, eight weeks, sixteen weeks. How long are we going to give this drug to work?’ I check in with them periodically. My first touch point is always at the four-week mark, no matter what drug I start them on. That's partly to kind of see what the insurance piece has been, and make sure they continue on the regimen, but also to keep that touch point and make sure I can reassure them and help them move in the right direction. One thing, especially for patients with skin of color, is when they see the AD fade, the dark marks stay, so they may think the treatment's not working, when in fact this is just a footprint of what was, so that additional counseling can help them adhere to treatment.

But then after four weeks I see them back three months later, I get them to that point where things are in good shape, and then we spread out the visit, so again that hand holding, I think, helps the process, but I also tell them, you know what, if we're not where we need to be, I have a lot of other targeted treatments that I can give you. We'll just take it step by step, and just know this is not your only option, but it is a lot of counseling, hand-holding, and remembering at the end of the day this is hard on them. They're living with their AD every single day, so all we can do is just help them and guide them through the process.

 How do you address concerns over adherence in atopic dermatitis management?

I don't always ask them about how often they are taking this medicine, or how often they are injecting it. I ask them, ‘How many injections did you forget, how many pills did you forget?’ I think that kind of opens the door to a more truthful answer. You may not necessarily get the right answer that you're looking for, but part of it is that part of it is just looking at their skin. If there is a drug that should be working and an individual's not getting better. I start to wonder, ‘What is going on here?’

I remember actually one of my patients back in the day, and this was for psoriasis, not for eczema. It was a child who was on one of the blockbuster medicines that worked so fast. Every visit he would see me, nothing had changed, and I was like, this is very odd. So I asked the mom, are you sure he's taking it? And she was like, oh yeah, he's doing his own injections. I'm like, can you just go and check?

They went to the basement; there was a fridge full of injectable medicine. Then we realized, okay, someone needs to be monitoring it. But you have that gut instinct. I think we're kind of like detectives in dermatology, where you get that spidey sense that tells you something is off. Then I start to look for other reasons why their skin is not responding, and sometimes adherence becomes the main reason.

You presented during a session titled ‘Medical Crossfire.’ What atopic dermatitis treatments were highlighted during this panel discussion?

We did something fun this year where each of us decided to take a drug class and really advocate for that specific drug class, whether or not we feel that way, but we were going to go to town. This is our drug; everything about it is number one, everybody else is number two. We're really going to help the audience see in that art of therapy selection why you would pick one drug class versus another, and how you can best match the treatment to the person in front of you.

We're using an ‘Avengers’ theme, so each of the drugs is going to be represented by an Avenger. Hopefully, there are some Marvel universe people who are watching this who are interested. I think it's a very unique approach, and hopefully it'll be memorable for the audience. They can take some key pearls back to clinical practice.

What developments are you most excited about right now outside of this conference?

 I'm the host of the Medical Sisterhood, which is a podcast that I developed a little over a year ago with the help of HCPLive. It is dedicated to women's empowerment in dermatology, and I love that it's really kind of taken a life of its own at this point, where we're really helping not only women in dermatology, but also across the landscape. Women who are professionals, working moms, really. Helping them to better understand how they can reach work-life balance, and better understand the challenges that everybody goes through.

It’s to help people kind of see that what you see on the outside is oftentimes people's highlight reel, but there's a lot of behind the scenes that everyone goes through. That can hopefully help ground them. Thus far, we've been focusing on work-life balance and establishing that sisterhood. Moving forward, we're going to give it more of a medical twist and see how we can better apply this sisterhood to having more connections in the field of dermatology.

Disclosures: AbbVie, Apogee, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Johnson & Johnson, LEO, Lilly USA, Novartis, Regeneron, Sanofi-Genzyme, Takeda, UCB, Pfizer, and others.

Nguyen H, Bunick C, Cotter D, Shahriari M. Medical Crossfire and Clinical Case Challenge. Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.

OX40-targeting agents represent a notable shift in atopic dermatitis therapeutics, aiming beyond cytokine suppression toward potential immune “retraining” and disease modification, albeit with slower onset and close safety scrutiny after phase 3 signals. Effective management increasingly hinges on expectation-setting and structured follow-up to support persistence through variable response timelines and payer hurdles. Counseling is particularly important in skin of color, where postinflammatory dyspigmentation may outlast active dermatitis and be misread as treatment failure. Adherence assessment benefits from nonjudgmental questioning and clinical pattern recognition.

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Q&A: What Are the Most Exciting New Atopic Dermatitis Developments? With Mona Shahriari, MD

A secret shopper study led by Yale School of Medicine researchers found 45 of 49 websites (91.8%) selling 

glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

 issued a prescription to a simulated patient, and approximately 67% of online sellers required no interaction with a clinician at all.

, comes at a time when compounded GLP-1 RAs have proliferated online alongside partnerships between branded manufacturers and telehealth platforms, with nearly 1 in 8 adults reporting current use of a GLP-1 drug and close to 20% of GLP-1 RA users obtaining their prescriptions online.

“While telehealth platforms have increased patient access to GLP-1 RAs, our findings suggest that some platforms do so through impersonal care that prioritizes quick prescriptions over comprehensive care,” wrote investigators.

Prior work from the same Yale research group reviewed website content alone and suggested limited clinician engagement in online compounded GLP-1 RA sales. The new study tested clinician engagement directly, using a simulated patient profile, dubbed Patient Sim, to solicit prescriptions from 49 websites identified as advertising GLP-1 RAs.

Online GLP-1 RA Prescribing Speed and Clinician Interaction Rates

Per study protocol, Patient Sim solicited a GLP-1 RA prescription from each of the 49 websites between August and December 2025, all of which sold either compounded or branded GLP-1 RAs and served patients in Connecticut. Every website relied on a questionnaire to collect height, weight, weight loss goals, and medical history, and 45 of 49 (91.8%) also incorporated a synchronous or asynchronous call into the process.

Across the 49 websites, 45 (91.8%) issued a GLP-1 RA prescription and 32 (65.3%) mailed the medication to Patient Sim. The median time from request to prescription was 1 day or less (IQR, ≤1-2 days), and 2 prescriptions (4.4%) were issued in 5 minutes or less. 

Clinicians involved in the prescribing process were predominantly physicians, with MDs or DOs accounting for 28 of 49 websites (57.1%) and advanced practice registered nurses accounting for 17 (35.7%), while 4 websites (8.2%) offered no option to ask a clinician questions at all.

Compounded GLP-1 RAs, Added Supplements, and Prescribing oversight gaps

Among the 45 websites prescribing a GLP-1 RA, 39 (86.7%) issued a compounded formulation and 6 (13.3%) issued a branded product. Subcutaneous formulations accounted for 39 prescriptions (86.7%), with 5 (11.1%) sublingual and 1 (2.2%) oral. Added supplements, including vitamin B12, B6, B3 or NAD+, glycine, or carnitine, accompanied 27 of 45 prescriptions (60.0%), and 15 (33.3%) of all prescriptions included B12 specifically.

Oversight gaps emerged throughout the prescribing process. 9 of 45 GLP-1 RAs (20.0%) were prescribed with only an upper body photo despite a stated requirement for a full body photo or a photo on a scale. 34 (75.6%) were automatically charged and shipped once a prescription was approved, without a documented reassessment step.

Three clinicians issued GLP-1 RA prescriptions to Patient Sim across 2 or more separate websites. One website initially denied a prescription based on internal data indicating an active prescription elsewhere, then issued it once Patient Sim requested a refund. Of the 32 GLP-1 RA prescriptions Patient Sim obtained, the median supply was 1.0 months (IQR, 1.0-1.6) at a median price of $230.00 per month (IQR, $163.80-$294.70), with 30 sourced from 20 unique compounding pharmacies.

Chetty AK, Chen AS, Ross JS, Ramachandran R. Online prescribing of GLP-1 receptor agonists: a secret shopper study. Presented at: 10th Annual Heart in Diabetes (HiD) meeting; June 19-21, 2026; Philadelphia, PA.

Poll: 1 in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes or another condition, even as half say the drugs are difficult to afford. KFF. Accessed March 8, 2026. 

https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/

Chetty AK, Chillakanti M, Ramachandran R, Ross JS, Chen AS. Online advertising of compounded glucagon-like peptide-1 receptor agonists. 

. 2025;6:e245018. doi:10.1001/jamahealthforum.2024.5018

A Yale-led secret shopper evaluation of 49 Connecticut-facing websites selling compounded or branded GLP-1 receptor agonists found rapid, low-touch prescribing. Prescriptions were issued by 45 sites (91.8%), commonly within a day, and two were approved within minutes; 67% required no clinician interaction. Most prescriptions were for compounded products, frequently bundled with adjunct “supplements” such as B vitamins or NAD+. Multiple workflow gaps were observed, including limited identity/anthropometric verification and automatic charging/shipping without documented reassessment.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Type 2 Diabetes

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Yale Study: Two-Thirds of Online GLP-1 Prescriptions Require No Clinician-Patient Interaction

Videos

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

What is the Most Contested Issue in Atopic Dermatitis Today? With Mona Shahriari, MD

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema. 

Delgocitinib Cream Shows Consistent CHE Efficacy Across Several Subgroups

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients

Pulmonary nurse practitioner at Prisma Health in Greenville, South Carolina, and president elect, Association of Pulmonary APPs (APAPP)

Sarah Tomashefski, MSN, says persistent myths about who gets AATD and a failure to screen patients with any obstructive lung disease are driving a diagnostic gap APPs are uniquely positioned to close.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Positioning New Agents and Overcoming Real-World Barriers for Asthma and COPD

Harrison Nguyen, MD, MBA, MPH, is a double board-certified dermatologist/Mohs micrographic surgeon and clinical researcher in Houston, Texas.

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.

Individualizing Treatment Selection in Atopic Dermatitis, With Harrison Nguyen, MD, MBA, MPH

At RAD 2026, Nguyen speaks on key highlights from his “Medical Crossfire” session, touching on the atopic dermatitis treatment landscape.

Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH

David Rosmarin, MD, discussed STAT6 inhibitors, ITK inhibitors, bispecifics, hand eczema, and endpoints at the RAD 2026 Conference.

STAT6, ITK Inhibitors, IL-31, & IL-18 Headline Burgeoning Pipeline in Atopic Dermatitis, with David Rosmarin, MD

At SDPA 2026, Shanna Miranti, PA-C, outlined how dermatology PAs can sharpen diagnostic speed and accuracy through structured visual practice and algorithm-based thinking.

Latest News

MOMENTUM: Lower Kidney Function Could Signal Hypercortisolism in Resistant Hypertension

Dupilumab Improves Growth, Skin, & Caregiver Burden Across Pediatric AD Spectrum

Lipoprotein(a) Testing Prevalence Remains Just 1.1% in US Adults

Q&A: What Are the Most Exciting New Atopic Dermatitis Developments? With Mona Shahriari, MD

Yale Study: Two-Thirds of Online GLP-1 Prescriptions Require No Clinician-Patient Interaction